Mediwound (MDWD)
NASDAQ:MDWD
Want to see MDWD full AI Analyst Report?
MDWD Stock Chart & Stats
$17.72
-$0.64(-3.70%)
At close: 4:00 PM EST
$17.72
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$14.90 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)83.89K
Market Cap
$212.85M
Enterprise Value$180.49M
Total Cash (Recent Filing)$53.14M
Total Debt (Recent Filing)$8.77M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 27, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding12,845,664
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue10.64
Enterprise Value/Gross Profit55.47
Enterprise Value/Ebitda-12.39
Forecast
1Y Price Target
$30.00Price Target Upside69.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.71
Revenue Forecast (FY)$24.76M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentVALUE Phase III trial design is supported by case studies and supplemental clinical data, which strengthens the clinical rationale for EscharEx and may improve prospects for regulatory approval.
Government Contracts And PreparednessBARDA contract and related government procurement position NexoBrid within United States emergency preparedness, providing external validation, durable government revenue, and potential to accelerate clinical and commercial adoption.
Manufacturing CapacityAn expanded manufacturing facility is operational and could materially increase production capacity for NexoBrid and support commercial supply once required regulatory clearances are achieved.
Bears Say
Dependence On Public FundingHeavy reliance on government contracts and development services creates dependency on public funding cycles and budget decisions, increasing revenue volatility and exposure to policy-related setbacks.
Regulatory And Commercialization RiskCompany upside is contingent on successful regulatory approval and effective commercialization of EscharEx, creating execution and outcome risk that could limit stock performance.
Revenue Sensitivity To Procurement DelaysGovernment procurement delays and disrupted budget approvals have caused timing-related revenue recognition shortfalls and interrupted NexoBrid sales, pressuring near-term financial results.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.90 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $212.85M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is May 27, 2026 which is in 27 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Mar 05, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.09.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.65.
How many shares outstanding does Mediwound have?
Mediwound has 12,845,664 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went down -0.852%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mediwound Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (69.30% Upside)
$30.00 (69.30% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 9.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.91%
12-Months-Change
Fundamentals
Return on Equity
-65.79%
Trailing 12-Months
Asset Growth
17.36%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflects meaningful operational and strategic progress — a sixfold manufacturing capacity expansion, active Phase III enrollment for EscharEx, expanded indication work (DFU and pressure ulcers), numerous industry collaborations, substantive real-world data for NexoBrid, and a strengthened cash position following a $30M financing — all of which support a multiyear growth thesis. Offsetting these positives are near-term financial challenges: steep Q4 revenue decline (≈-67%), a full-year revenue drop (≈-16%), higher R&D spend and widening operating and EBITDA losses, reliance on government awards and pending regulatory approvals for the new facility, and elevated cash burn. Overall, operational momentum is evident but financial performance and timing risks temper the outlook.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(69.30% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
―
Tevogen Bio Holdings
―
Ownership Overview
―
Insiders
4.68% Mutual Funds
7.83% Other Institutional Investors
83.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---